Antibody-Based Therapy for Transplantation-Eligible Patients with Multiple Myeloma

This editorial explores the evolving landscape of first line treatment for transplantation eligible patients with newly diagnosed multiple myeloma. It highlights the PERSEUS trial, which evaluates the addition of daratumumab to the standard VRd regimen (bortezomib, lenalidomide, dexamethasone). Results show significantly improved progression free survival and deeper responses with the quadruplet therapy (D VRd), without compromising transplant eligibility. The piece also discusses ongoing questions around long-term maintenance, cost, toxicity, and overall survival, emphasizing the need for balanced treatment decisions in this “golden age” of myeloma therapies.

This editorial explores the evolving landscape of first line treatment for transplantation eligible patients with newly diagnosed multiple myeloma. It highlights the PERSEUS trial, which evaluates the addition of daratumumab to the standard VRd regimen (bortezomib, lenalidomide, dexamethasone). Results show significantly improved progression free survival and deeper responses with the quadruplet therapy (D VRd), without compromising transplant eligibility. The piece also discusses ongoing questions around long-term maintenance, cost, toxicity, and overall survival, emphasizing the need for balanced treatment decisions in this “golden age” of myeloma therapies.